ClinicalTrials.gg
CompletedNCT07371260Rév In MASUpdated Oct 30, 2026

Effects of Virtual Reality With Multisensory Stimulation on Emotional and Behavioral Disorders in Individuals With Acquired Brain Injury and Disability Requiring Institutional Care: a Single Case Experimental Design (SCED) Study.

An interventional study of Virtual reality in Brain Injury, Virtual Reality and Behavior, sponsored by Hopital La Musse. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Hopital La Musse · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Brain Injuries with a site in France — 18 open to participants now, 19 under way, none of them phase 3. Brain Injuries · France.

Enrollment
35th of 36
3 · median 46
Started
2026
with 4 others
No phase
26 of 72
6 open now
Registered
69th of 72
by date

Among the 72 studies in Brain Injuries with a site in France, this one is the 35th largest by enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2026, is one of 26 with no phase, and was the 69th registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

18 of the 72 studies in Brain Injuries with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Brain Injuries with a site in France, or all of them as a file.
02

Study summary

Acquired brain injuries (ABIs) frequently cause emotional and behavioral disorders that impair independence and quality of life, particularly in institutions. Virtual reality (VR), already used in various mental and neurological disorders, offers therapeutic potential that remains largely unexplored in this context.

Multisensory devices offer enhanced immersion that can potentially increase the relaxation and calming effect. Their use in specialized care home (SCH) could provide additional support for care.

The main objective of the study is to measure the effect of an 8-week multisensory VR relaxation program on the most significant emotional and behavioral disorders in adults with acquired brain injury living in SCH. The SCED method with multiple baselines across subjects (ABA) is used with three adult residents with ABCI and behavioral disorders living in SCH. The study consists of three phases (baseline, intervention, follow-up), during which the three main emotional and behavioral disorders of each resident are assessed weekly based on observations made throughout the week. Additional measures include the assessment of the socio-emotional profile by the care team (ECCSEG) and the emotional distress experienced by residents (QOLIBRI), collected twice per phase. The intervention consists of eight weeks of VR relaxation (VirtySens®), with two 15-minute sessions per week.

All measurements taken during the experiment will be anonymized and used only by the investigators, who are fully aware of the European GDPR (General Data Protection Regulation) concerning the protection of personal data.

03

Conditions studied

  • Brain Injury
  • Virtual Reality
  • Behavior
  • Emotion
  • Well-being

Keywords

  • Acquired Brain Injury
  • Behavior
  • Emotion
  • Well-being
  • Virtual Reality
  • Multisensory
  • Specialized Care Home
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resident aged over 18
  • Diagnosis of stroke, traumatic brain injury, tumor, or cerebral anoxia for more than 3 years.
  • Living in a nursing home for at least 6 months
  • Presence of one or more emotional and behavioral disorders during initial assessments (NPI-ES) for at least 3 months.
  • Sufficient cognitive abilities to understand instructions and answer questions using a Likert scale.
  • Normal or corrected visual acuity
  • Resident affiliated with the social security system

Exclusion criteria

Exclusion Criteria:

  • Motor or sensory disorders incompatible with the use of VR
  • Unstabilized photosensitive epilepsy or presence of a seizure in the past year
  • Change in the prescription of neuroleptic treatments, antidepressants, benzodiazepines, sedatives, anxiolytics, mood stabilizers, antiepileptics, or betablockers within the last 3 months.
  • Unstabilized major psychiatric disorders.
  • Craniectomy
  • Limited range of cervical movement due to orthopedic disorders
  • Moderate or severe hearing loss not compensated by a hearing aid
  • Anosmia
  • Asthma
  • Pregnant women or women suspected of being pregnant
  • Breastfeeding women
  • Neurocognitive disorders preventing understanding of instructions during assessments
  • The resident is included in another research protocol
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Intervention

    VR

    Other: Virtual reality

Interventions

  • OtherVirtual reality

    The intervention will consist of 8 weeks with two weekly virtual relaxation sessions using the VirtySens® multisensory device, lasting 15 to 20 minutes.

06

What researchers measure

Primary outcomes

  1. NPI-ES

    The primary outcome measure is the weekly NPI-ES score, calculated for the three most prominent emotional and behavioral disturbances in each participant. This score is calculated from systematic observations made daily over five consecutive days, during two standardized periods of the day: (1) lunch and (2) a group activity in the afternoon.

    Time frame: Twice a week, for 21 weeks

Secondary outcomes

  1. ECCSEG : The Geneva Scale of Socio-Emotional Behavior Changes

    The Geneva Socio-Emotional Behavior Change Scale (ECCSEG) was developed by Beni et al. (2017) to assess socio-emotional disorders frequently encountered after a TBI, although it can also be used in other etiological contexts. The ECCSEG questionnaire is completed by the neuropsychologist together with the care team, which includes at least one registered nurse, one nursing assistant or medical-psychological assistant, one special education teacher, and one psychomotor therapist during weekly team meetings. The team agrees to evaluate the 22 items on each participant's questionnaire. A total score is then calculated by adding up all the scores per item. The ECCSEG questionnaire is completed twice per phase: midway through and at the end of the phase.

    Time frame: in the middle and at the end of each phase of the SCED (baseline, intervention, follow-up). 6 evaluations

  2. The QOLIBRI Emotion Questionnaire

    The QOLIBRI Emotion Questionnaire is a tool specifically designed for people with brain injuries, which aims to gather subjective perceptions of patients' quality of life.

    Time frame: Twice at baseline, twice during the intervention, and twice during follow-up (6 evaluations).

  3. Sensory capsule satisfaction survey

    Each resident is asked: "Are you satisfied with using the sensory capsule? On a scale of 1 to 5 (Likert). 1 = Not at all; 2 = A little; 3 = Moderately; 4 = Quite a lot; 5 = Very much." Why? Residents will answer this question twice during the intervention.

    Time frame: Twice during the intervention

  4. The Simulator Sickness Questionnaire (SSQ)

    The Simulator Sickness Questionnaire (SSQ) is currently the gold standard test for objectively measuring cybersickness.

    Time frame: Twice during the intervention

  5. The RV Presence Questionnaire

    The Presence Questionnaire (74): consisting of 19 items on a 7-point scale, it measures the feeling of presence.

    Time frame: Twice during the intervention

07

Study locations

1 site
  • Hôpital La Musse
    Saint-Sébastien-de-Morsent, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2026 to primary completion in Sep 2026, 0 months.

Of 285 non-industry interventional studies with no phase under Brain Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 0 months is below that.

Counting every sponsor, half of 298 studies reached it within 24 months; a quarter within 12 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Feb 2026 → Sep 2026, primary completion Dec 2026 → Sep 2026 and completion Feb 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 27, 2026
StartActual
Sep 30, 2026was Feb 2026
Primary completionActual
Sep 30, 2026was Dec 2026
CompletionActual
Oct 15, 2026was Feb 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 30, 2026
Start date
Feb 15, 2026→Sep 30, 2026 (actual)
Oct 30, 2026
Primary completion
Dec 31, 2026→Sep 30, 2026 (actual)
Oct 30, 2026
Study completion
Feb 1, 2027→Oct 15, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Completed
    Start date Feb 15, 2026→Sep 30, 2026 (now actual)
    Primary completion Dec 31, 2026→Sep 30, 2026 (now actual)
    Study completion Feb 1, 2027→Oct 15, 2026 (now actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07371260
Lead sponsor
Hopital La Musse
Responsible party
Sponsor
First posted
Jan 27, 2026
Start date
Sep 30, 2026
Primary completion
Sep 30, 2026
Completion
Oct 15, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion